Previous close | 1.3500 |
Open | 1.3400 |
Bid | 1.3100 x 1000 |
Ask | 1.5000 x 1100 |
Day's range | 1.2500 - 1.4204 |
52-week range | 0.4600 - 3.6300 |
Volume | |
Avg. volume | 1,516,656 |
Market cap | 30.694M |
Beta (5Y monthly) | 1.13 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.4880 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.29 |
MONT-SAINT-GUIBERT, Belgium, December 21, 2022--Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (the "Company") (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today provides an update on its Celyad 2.0 business strategy which has been adopted and implemented over the last few months.
MONT-SAINT-GUIBERT, Belgium, November 10, 2022--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the "Company"), a biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today provided an update on its financial results and recent business developments for the fiscal quarter ended September 30, 2022.
MONT-SAINT-GUIBERT, Belgium, October 12, 2022--Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD), a biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today provided an update on its strategic business model, clinical trial programs, and the related operational and organizational steps and cost-saving measures that it will undertake.